Daunorubicin

Generic Name: Daunorubicin

Brand Names: Cerubidine, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₀

CAS Number: 20830-81-3

Unique Ingredient Identifier: ZS7284E0ZP

Background: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

Indication: For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor

Associated Therapies: -

Clinical Trials

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

Conditions: Adult Acute Lymphoblastic Leukemia

Interventions: Drug: PLD
Drug: DNR

First Posted Date: 2018-02-05

Last Posted Date: 2018-02-05

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT03419494

Locations: 🇨🇳
Affiliated Hospital of Guangdong Medical University, Guangdong, Guangdong, China

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

Not Applicable

Recruiting

Conditions: Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: Dexamethasone intermittent
Drug: Dexamethasone continuous
Drug: Second phase of induction
Drug: Standard induction therapy
Drug: Standard consolidation therapy
Drug: Dexamethasone
Drug: Methylprednisolone
Drug: Idarubicin
Drug: Daunorubicin
Drug: Bortezomib

First Posted Date: 2018-01-04

Last Posted Date: 2020-02-05

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 4000

Registration Number: NCT03390387

Locations: 🇷🇺
Morozov Children's Municipal Clinical Hospital, Moscow, Russian Federation
🇦🇲
prof. R.O.Eolyan Hematology Center, Ereván, Armenia
🇷🇺
Transbaikal Regional Oncology Dispensary, Chita, Russian Federation

and more 45 locations

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Alvocidib
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2017-10-02

Last Posted Date: 2023-11-15

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 32

Registration Number: NCT03298984

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Columbia University, New York, New York, United States

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Phase 2

Recruiting

Conditions: Childhood Cancer
Acute Lymphoblastic Leukemia
Down Syndrome

Interventions: Drug: Daunorubicin
Drug: Prednisolone
Drug: Vincristine
Drug: Epirubicin
Drug: E-coli L-asparaginase
Drug: 6-Mercaptopurine
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Cytarabine
Drug: Cyclophosphamide

First Posted Date: 2017-09-18

Last Posted Date: 2022-09-28

Lead Sponsor: National Hospital Organization Nagoya Medical Center

Target Recruit Count: 60

Registration Number: NCT03286634

Locations: 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Subang Jaya Medical Centre, Subang Jaya, Malaysia

and more 7 locations

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Azacitidine
Drug: Decitabine
Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Combination Product: ITMHA
Drug: Idarubicin
Drug: Fludarabine
Drug: Mitoxantrone
Drug: Sorafenib
Drug: Erwinia asparaginase
Drug: G-CSF
Drug: Dexrazoxane
Drug: Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Biological: Stem Cell Transplant

First Posted Date: 2017-05-23

Last Posted Date: 2024-05-29

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 206

Registration Number: NCT03164057

Locations: 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸
Children's Hospital of Central California, Madera, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 7 locations

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Hematologic Malignancy

Interventions: Drug: Entospletinib
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2017-05-01

Last Posted Date: 2020-03-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 9

Registration Number: NCT03135028

Locations: 🇯🇵
University of Fukui Hospital, Fukui, Japan
🇯🇵
Tokai University Hospital, Kanagawa, Japan
🇯🇵
Tohoku University Hospital, Miyagi, Japan

and more 3 locations

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date: 2017-04-18

Last Posted Date: 2024-11-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 790

Registration Number: NCT03117751

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸
St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺
The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Biological: PF-06747143
Drug: Cytarabine
Drug: Azacitidine
Drug: Daunorubicin
Drug: Decitabine

First Posted Date: 2016-11-03

Last Posted Date: 2019-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT02954653

Locations: 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
Banner-University Medical Center Tucson, Tucson, Arizona, United States

and more 1 locations

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Daunorubicin

First Posted Date: 2016-09-26

Last Posted Date: 2022-01-14

Lead Sponsor: Tara Lin

Target Recruit Count: 18

Registration Number: NCT02914977

Locations: 🇺🇸
University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Phase 4

Conditions: Acute Lymphoblastic Leukemia (ALL)

Interventions: Drug: Prednisolone
Drug: Dexamethasone
Drug: L-Asparaginase
Drug: Vincristine
Drug: Methotrexate
Drug: Doxorubicin
Drug: Daunorubicin
Drug: Cyclophosphamide
Drug: 6-Mercaptopurine
Drug: Cytarabine
Drug: Thioguanine
Drug: Fludarabine
Drug: Imatinib

First Posted Date: 2016-09-09

Last Posted Date: 2016-09-30

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 500

Registration Number: NCT02894645

Locations: 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬
National University Hospital, Singapore, Singapore

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy